Search clinical trials for: VTX-2337

Total 1924 results

Celgene

Completed

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

Lymphoma | Advanced Solid Tumors

United States
Celgene
Stanford University

Terminated

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Low Grade B Cell Lymphoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Celgene

Terminated

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Carcinoma, Squamous Cell

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
Celgene

Terminated

A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab

Squamous Cell Carcinoma of the Head and Neck

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Recurrent Renal Cell Carcinoma | Stage IV Skin Melanoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Breast Cancer | Recurrent Breast Carcinoma | Recurrent Colorectal Carcinoma | Colorectal... and other conditions

United States
Allysta Pharmaceutical

Completed

H-1337 Ophthalmic Solution Phase 1/2

Glaucoma, Open-Angle

United States
Shionogi

Completed

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet

Obesity

United States
Celgene
Gynecologic Oncology Group

Completed

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Cancer

United States
Celgene

Completed

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

United States
Sumitomo Pharma America, Inc.
Syneos Health

Terminated

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Neoplasms

United States
Boehringer Ingelheim

Completed

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

Parkinson Disease

United States, Canada
Chong Kun Dang Pharmaceutical

Unknown

Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

Hypertension | Dyslipidemias

Korea, Republic of
Shionogi

Completed

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

Obesity

United States
Shionogi

Completed

Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects (OLE)

Obesity

United States
Boehringer Ingelheim

Completed

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

Alzheimer Disease

United States, Canada
Ludwig Institute for Cancer Research
Celgene; Cancer Research Institute, New York City; MedImmune LLC

Completed

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Ovarian Cancer

United States, Switzerland
Chong Kun Dang Pharmaceutical

Completed

A Study to Investigate Drug Interaction Between D326, D337, and D013 in Healthy Male Subjects

Hypertension | Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386

Hypertension and Dyslipidemia

Korea, Republic of
Amgen

Completed

A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects

Stomach Neoplasms

Japan
Sosei

Completed

A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia

Fibromyalgia

United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause

Menopause

Belgium, Finland, Sweden, South Africa, Croatia, United Kingdom, France, Romania, Ukraine, Spain, Poland, Hungary, Czech Republic, Mexico, Netherlands
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

Neoplasms | Tumors

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348

Hypertension and Dyslipidemia

Korea, Republic of
Amgen

Terminated

Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

Stomach Neoplasms

Belgium, France, Italy, Spain, Czechia, Poland, United States, Korea, Republic of, Russian Federation, Canada, United Kingdom, Australia, Austria, Germany, Hungary, Greece, Peru, Chile
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

Fibromyalgia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

Neoplasms

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348 (CKD-348)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(2)

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(3)

Hypertension and Dyslipidemia

Korea, Republic of
Takeda

Completed

A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects

Clinical Pharmacology

Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder

Depressive Disorder | Depression | Major Depressive Disorder
Turino, Gerard, M.D.
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-391(2)

Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg

Hypertension and Dyslipidemia

Korea, Republic of
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause

Hot Flashes | Menopause | Sleep Disorders
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(6)

Hypertension | Dyslipidemias

Korea, Republic of
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348(5)

Hypertension and Dyslipidemia

Korea, Republic of
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Major Depressive Disorder
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause

Vasomotor Symptoms

United States
Chong Kun Dang Pharmaceutical

Completed

Clinical Study to Evauate the Pharmacokinetic Profiles and Safety of CKD-348 in Healthy Volunteers

Healthy

Korea, Republic of
D. Western Therapeutics Institute, Inc.

Recruiting

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma Open-Angle Primary

United States

Search clinical trials for: VTX-2337

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations